atrasentan has been researched along with Albuminuria in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Bakris, G; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Rossing, P; Xie, D | 1 |
| Bakris, GL; Correa-Rotter, R; de Zeeuw, D; Gansevoort, RT; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, DE; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Tobe, S; Waijer, SW | 1 |
| Fernandez-Fernandez, B; Ortiz, A | 1 |
| Chi, J; Dong, B; Huang, Y; Lv, W; Wang, YG; Zhou, Y | 1 |
| Bakris, G; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Koomen, JV; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Stevens, J; Tobe, SW | 1 |
| Awni, WM; J Brennan, J; Klein, CE; L Andress, D; Lin, CW; Mostafa, NM | 1 |
| de Zeeuw, D; Heerspink, HJL; Koomen, JV; Mostafa, NM; Parving, HH; Stevens, J | 1 |
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; de Zeeuw, D; Houser, M; Kohan, D; Lambers Heerspink, HJ; Makino, H; Parving, HH; Perkovic, V; Pritchett, Y; Remuzzi, G; Tang, H; Tobe, SW; Toto, R; Viberti, G | 1 |
| Andress, DL; Bijlsma, MJ; de Zeeuw, D; Heerspink, HJ; Kröpelin, TF; Parving, HH; Persson, F | 1 |
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; de Zeeuw, D; Hou, FF; Kitzman, DW; Kohan, DE; Lambers Heerspink, HJ; Makino, H; Parving, HH; Perkovic, V; Remuzzi, G; Tobe, SW; Toto, R | 1 |
| Kang, WL; Xu, GS | 1 |
| Allison, SJ | 1 |
| Avramut, MC; Boels, MG; Dane, MJ; Gröne, HJ; Koster, AJ; Koudijs, A; Lee, DH; Rabelink, TJ; van den Berg, BM; van der Vlag, J; van Faassen, E; van Zonneveld, AJ | 1 |
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; Davis, JW; de Zeeuw, D; Heerspink, HJ; Idler, K; Kohan, DE; Liu, M; Makino, H; Parving, HH; Perkovic, V; Remuzzi, G; Tobe, SW; Toto, R | 1 |
| Andress, DL; Audhya, P; Garimella, T; Kohan, DE; Molitch, M; Pritchett, Y; Wen, S | 1 |
| Ritz, E; Wenzel, RR | 1 |
| Andress, DL; Brennan, J; Coll, B; Kohan, DE; Molitch, M; Pritchett, Y | 1 |
| Horio, T; Johnson, RJ; Kangawa, K; Kawano, Y; Suga, S; Yasui, N; Yoshihara, F | 1 |
1 review(s) available for atrasentan and Albuminuria
| Article | Year |
|---|---|
Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Albuminuria; Atrasentan; Bosentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Heart Failure; Humans; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic | 2021 |
9 trial(s) available for atrasentan and Albuminuria
| Article | Year |
|---|---|
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
Topics: Aged; Albuminuria; Atrasentan; Causality; Creatinine; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Reduction Behavior; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome | 2021 |
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
Topics: Albuminuria; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Renal Insufficiency; Renal Insufficiency, Chronic | 2021 |
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
Topics: Albuminuria; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Humans; Kidney | 2021 |
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Biological Variation, Population; Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Metabolic Clearance Rate; Renal Elimination; Renal Insufficiency; Severity of Illness Index; Sodium | 2018 |
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Endothelin-1; Female; Humans; Kidney Function Tests; Lipids; Male; Middle Aged; Pyrrolidines | 2014 |
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
Topics: Aged; Albuminuria; Atrasentan; Body Fluids; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pyrrolidines; Weight Gain | 2015 |
Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Topics: Aged; Albuminuria; Asia; Asian People; Atrasentan; Bilirubin; Body Fluids; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; North America; Pyrrolidines; Treatment Outcome; Weight Gain; White People | 2017 |
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Incidence; Male; Middle Aged; Pyrrolidines; Renin-Angiotensin System; Treatment Outcome | 2011 |
Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Topics: Aged; Albuminuria; Atrasentan; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Edema; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Hispanic or Latino; Humans; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Renin-Angiotensin System | 2012 |
8 other study(ies) available for atrasentan and Albuminuria
| Article | Year |
|---|---|
Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease.
Topics: Albuminuria; Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Humans; Pyrrolidines | 2021 |
Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy.
Topics: Aged; Albuminuria; Atrasentan; Body Weight; Clinical Trials, Phase II as Topic; Creatinine; Diabetic Nephropathies; Double-Blind Method; Edema; Female; Humans; Kidney Function Tests; Male; Middle Aged; Randomized Controlled Trials as Topic | 2018 |
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
Topics: Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrasentan; Bone Density Conservation Agents; Diabetic Nephropathies; Endothelin Receptor Antagonists; Ergocalciferols; Female; Fumarates; Humans; Losartan; Male; Middle Aged; Office Visits; Pyrrolidines; Randomized Controlled Trials as Topic; Research Design; Statistics as Topic; Urine Specimen Collection | 2015 |
Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy.
Topics: 3' Untranslated Regions; Albuminuria; Animals; Antioxidants; Atrasentan; Biomarkers; Cell Line; Diabetic Nephropathies; Disease Models, Animal; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation; Glucuronidase; Humans; Kidney Function Tests; Kidney Tubules; Klotho Proteins; Male; Mice; MicroRNAs; Middle Aged; Mitochondria; Promoter Regions, Genetic; Pyrrolidines; RNA Interference | 2016 |
Diabetic nephropathy: Atrasentan stabilizes the endothelial glycocalyx.
Topics: Albuminuria; Atrasentan; Diabetic Nephropathies; Endothelial Cells; Endothelium, Vascular; Glycocalyx; Humans; Pyrrolidines | 2016 |
Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy.
Topics: Albuminuria; Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin Receptor Antagonists; Glomerular Filtration Rate; Kidney Glomerulus; Male; Mice; Mice, Knockout; Pyrrolidines | 2016 |
Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?
Topics: Albuminuria; Atrasentan; Diabetic Nephropathies; Endothelins; Glomerular Filtration Rate; Humans; Proteinuria; Pyridines; Pyrimidines; Pyrrolidines; Renin-Angiotensin System; Treatment Outcome | 2011 |
Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms.
Topics: Albuminuria; Animals; Atrasentan; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Hypertrophy; Hypokalemia; Kidney; Kidney Diseases; Kidney Tubules; Male; Potassium; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B | 2003 |